Clinical Trials
19 trialsNCT00544115 2026-06-02
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Phase 2 Active not recruiting
NCT01849783 2022-05-11
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Phase 2 Completed
NCT00051311 2021-09-09
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02128230 2021-06-22
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Terminated
NCT00536601 2021-04-22
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Roswell Park Cancer Institute
Phase NA Completed
NCT01008462 2019-06-11
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00074490 2018-12-31
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00349778 2017-12-12
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
Stanford University
Phase 2 Completed
NCT00083915 2017-11-20
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
University of Arkansas
Phase 3 Completed
NCT00006184 2017-10-20
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00281879 2017-09-27
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00691015 2017-06-28
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01548573 2017-06-14
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
University of Iowa
Phase 2 Terminated
NCT00513474 2017-05-25
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Phase 1 Completed
NCT01110135 2017-05-24
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
Phase 2 Completed
NCT00083551 2015-11-23
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
University of Arkansas
Phase 3 Completed
NCT00577096 2015-04-06
Effects of Exercise in Combination With Epoetin Alfa
University of Arkansas
Phase NA Completed
NCT01653418 2014-10-15
V-BEAM
Washington University School of Medicine
Phase 2 Terminated
NCT00589563 2014-09-10
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
Phase 2 Completed